CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced the clinical launch of its ...
"The collaboration with Tempus will substantially augment our existing precision oncology capabilities. Northwestern Medicine will now offer next-generation sequencing to patients with earlier-stage ...
Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced select, preliminary, unaudited results for the fourth quarter and full ...
CHICAGO--(BUSINESS WIRE)-- Tempus AI, Inc. (TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced a collaboration to develop a companion ...
CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced xM for treatment response ...
CHICAGO--(BUSINESS WIRE)-- Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced the national launch of the ...
CHICAGO--(BUSINESS WIRE)-- Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced its participation in almost ...
Tempus AI is a Buy for long-term growth, driven by its shift to a data/AI platform and accelerating genomics volume fueling high-margin revenue. Strategic deals (AstraZeneca/Pathos) and the Paige ...
Tempus Next supports providers in closing gaps in care for eligible patients based on clinical guidelines. Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback